Search

Your search keyword '"Smith, Lisa L."' showing total 42 results
Start Over Author "Smith, Lisa L." Search Limiters Available in Library Collection
42 results on '"Smith, Lisa L."'

1. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

Author

Lee, Christine G, Heckman-Stoddard, Brandy, Dabelea, Dana, Gadde, Kishore M, Ehrmann, David, Ford, Leslie, Prorok, Philip, Boyko, Edward J, Pi-Sunyer, Xavier, Wallia, Amisha, Knowler, William C, Crandall, Jill P, Temprosa, Marinella, Group:, Diabetes Prevention Program Research, Bray, George A, Culbert, Iris W, Arceneaux, Jennifer, Chatellier, Annie, Dragg, Amber, Champagne, Catherine M, Duncan, Crystal, Eberhardt, Barbara, Greenway, Frank, Guillory, Fonda G, Herbert, April A, Jeffirs, Michael L, Kennedy, Betty M, Levy, Erma, Lockett, Monica, Lovejoy, Jennifer C, Morris, Laura H, Melancon, Lee E, Ryan, Donna H, Sanford, Deborah A, Smith, Kenneth G, Smith, Lisa L, St. Amant, Julia A, Tulley, Richard T, Vicknair, Paula C, Williamson, Donald, Zachwieja, Jeffery J, Polonsky, Kenneth S, Tobian, Janet, Ehrmann, David A, Matulik, Margaret J, Temple, Karla A, Clark, Bart, Czech, Kirsten, DeSandre, Catherine, Dotson, Brittnie, Hilbrich, Ruthanne, McNabb, Wylie, Semenske, Ann R, Caro, Jose F, Furlong, Kevin, Goldstein, Barry J, Watson, Pamela G, Smith, Kellie A, Mendoza, Jewel, Simmons, Marsha, Wildman, Wendi, Liberoni, Renee, Spandorfer, John, Pepe, Constance, Donahue, Richard P, Goldberg, Ronald B, Prineas, Ronald, Calles, Jeanette, Giannella, Anna, Rowe, Patricia, Sanguily, Juliet, Cassanova-Romero, Paul, Castillo-Florez, Sumaya, Florez, Hermes J, Garg, Rajesh, Kirby, Lascelles, Lara, Olga, Larreal, Carmen, McLymont, Valerie, Mendez, Jadell, Perry, Arlette, Saab, Patrice, Veciana, Bertha, Haffner, Steven M, Hazuda, Helen P, Montez, Maria G, Hattaway, Kathy, Isaac, Juan, Lorenzo, Carlos, Martinez, Arlene, Salazar, Monica, Walker, Tatiana, Hamman, Richard F, Nash, Patricia V, Steinke, Sheila C, Testaverde, Lisa, Truong, Jennifer, and Anderson, Denise R

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Clinical Sciences, Prevention, Clinical Trials and Supportive Activities, Nutrition, Clinical Research, Cancer, Cardiovascular, Diabetes, Aetiology, 2.2 Factors relating to the physical environment, Good Health and Well Being, Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Life Style, Metformin, Diabetes Prevention Program Research Group, Diabetes Prevention Program Research Group:, Medical and Health Sciences, Endocrinology & Metabolism, Biomedical and clinical sciences, Health sciences
Abstract

ObjectiveTo determine whether metformin or lifestyle modification can lower rates of all-cause and cause-specific mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.Research design and methodsFrom 1996 to 1999, 3,234 adults at high risk for type 2 diabetes were randomized to an intensive lifestyle intervention, masked metformin, or placebo. Placebo and lifestyle interventions stopped in 2001, and a modified lifestyle program was offered to everyone, but unmasked study metformin continued in those originally randomized. Causes of deaths through 31 December 2018 were adjudicated by blinded reviews. All-cause and cause-specific mortality hazard ratios (HRs) were estimated from Cox proportional hazards regression models and Fine-Gray models, respectively.ResultsOver a median of 21 years (interquartile range 20-21), 453 participants died. Cancer was the leading cause of death (n = 170), followed by cardiovascular disease (n = 131). Compared with placebo, metformin did not influence mortality from all causes (HR 0.99 [95% CI 0.79, 1.25]), cancer (HR 1.04 [95% CI 0.72, 1.52]), or cardiovascular disease (HR 1.08 [95% CI 0.70, 1.66]). Similarly, lifestyle modification did not impact all-cause (HR 1.02 [95% CI 0.81, 1.28]), cancer (HR 1.07 [95% CI 0.74, 1.55]), or cardiovascular disease (HR 1.18 [95% CI 0.77, 1.81]) mortality. Analyses adjusted for diabetes status and duration, BMI, cumulative glycemic exposure, and cardiovascular risks yielded results similar to those for all-cause mortality.ConclusionsCancer was the leading cause of mortality among adults at high risk for type 2 diabetes. Although metformin and lifestyle modification prevented diabetes, neither strategy reduced all-cause, cancer, or cardiovascular mortality rates.

Published
2021

2. Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program

Author

Aroda, Vanita R, Christophi, Costas A, Edelstein, Sharon L, Perreault, Leigh, Kim, Catherine, Golden, Sherita H, Horton, Edward, Mather, Kieren J, Bray, George A, Gadde, Kishore, Culbert, Iris W, Arceneaux, Jennifer, Chatellier, Annie, Dragg, Amber, Champagne, Catherine M, Duncan, Crystal, Eberhardt, Barbara, Greenway, Frank, Guillory, Fonda G, Herbert, April A, Jeffirs, Michael L, Kennedy, Betty M, Levy, Erma, Lockett, Monica, Lovejoy, Jennifer C, Morris, Laura H, Melancon, Lee E, Ryan, Donna H, Sanford, Deborah A, Smith, Kenneth G, Smith, Lisa L, St, Julia A, Amant, Richard T Tulley, Vicknair, Paula C, Williamson, Donald, Zachwieja, Jeffery J, Polonsky, Kenneth S, Tobian, Janet, Ehrmann, David A, Matulik, Margaret J, Clark, Bart, Czech, Kirsten, DeSandre, Catherine, Hilbrich, Ruthanne, McNabb, Wylie, Semenske, Ann R, Caro, Jose F, Furlong, Kevin, Goldstein, Barry J, Watson, Pamela G, Smith, Kellie A, Mendoza, Jewel, Wildman, Wendi, Liberoni, Renee, Spandorfer, John, Pepe, Constance, Donahue, Richard P, Goldberg, Ronald B, Prineas, Ronald, Calles, Jeanette, Ojito, Juliet, Rowe, Patricia, Cassanova-Romero, Paul, Castillo-Florez, Sumaya, Florez, Hermes J, Giannella, Anna, Kirby, Lascelles, Larreal, Carmen, Lara, Olga, McLymont, Valerie, Mendez, Jadell, Perry, Arlette, Saab, Patrice, Veciana, Beth, Haffner, Steven M, Hazuda, Helen P, Montez, Maria G, Hattaway, Kathy, Lorenzo, Carlos, Martinez, Arlene, Walker, Tatiana, Dabelea, Dana, Hamman, Richard F, Nash, Patricia V, Steinke, Sheila C, Testaverde, Lisa, Anderson, Denise R, Ballonoff, Larry B, Bouffard, Alexis, Bucca, Brian, Calonge, B Ned, Delve, Lynne, Farago, Martha, Hill, James O, Hoyer, Shelley R, Jenkins, Tonya, Jortberg, Bonnie T, Lenz, Dione, and Miller, Marsha

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Diabetes, Cardiovascular, Obesity, Estrogen, Clinical Research, Prevention, Nutrition, Aging, Clinical Trials and Supportive Activities, 3.1 Primary prevention interventions to modify behaviours or promote wellbeing, Prevention of disease and conditions, and promotion of well-being, Metabolic and endocrine, Diabetes Mellitus, Type 2, Female, Glucose Intolerance, Humans, Life Style, Male, Metformin, Sex Hormone-Binding Globulin, DPP Research Group, diabetes mellitus, hormone, life style, primary prevention, type 2, Clinical sciences, Public health
Abstract

Sex hormone binding globulin (SHBG) levels are reported to be inversely associated with diabetes risk. It is unknown whether diabetes prevention interventions increase SHBG and whether resultant changes in SHBG affect diabetes risk. The purpose of this analysis was to determine whether intensive lifestyle intervention (ILS) or metformin changed circulating SHBG and if resultant changes influenced diabetes risk in the Diabetes Prevention Program (DPP). This is a secondary analysis from the DPP (1996-2001), a randomized trial of ILS or metformin versus placebo on diabetes risk over a mean follow-up of 3.2 years. The DPP was conducted across 27 academic study centers in the USA. Men, premenopausal and postmenopausal women without hormone use in the DPP were evaluated. The DPP included overweight/obese persons with elevated fasting glucose and impaired glucose tolerance. Main outcomes measures were changes in SHBG levels at 1 year and risk of diabetes over 3 years. ILS resulted in significantly higher increases (postmenopausal women: p

Published
2020

4. The role of pre-trial attitudes about forensic science evidence : developing and testing a forensic evidence evaluation bias scale

Author

Smith, Lisa L., Bull, Raymond, and Holliday, Robyn

Subjects
614
Abstract

The unique decision making task entrusted to lay juries in adversarial legal systems has attracted the attention of legal psychologists for decades, but more recently technological advances in forensic science have highlighted the importance of understanding how jurors perceive this often ambiguous and complicated type of evidence. This thesis begins by investigating the forensic awareness of lay participants, and the ability of mock jurors to discriminate between varying probative values of forensic evidence. The findings suggest that the perception of weak forensic evidence is affected by contextual information, and there was wide disagreement among participants about the probative value of weak evidence. In an effort to explain the variance in perceived evidence strength, a measure of pre-trial attitudes about forensic science was developed (the Forensic Evidence Evaluation Bias Scale – FEEBS) and administered to 446 participants ranging from students, to jury eligible members of the public, to actual jury venire persons. The results of exploratory and confirmatory factor analyses identified two distinct clusters of attitudes measured by the FEEBS, which correspond conceptually to the hypothesised juror beliefs described in the CSI Effect literature. These attitudes were found to have a significant indirect effect on verdict preference, for trial vignettes describing murder, robbery, and sexual assault scenarios containing weak (or absent) forensic DNA evidence. The implications of these findings for voir dire hearings are discussed, with reference to the cognitive models of juror decision making and the CSI Effect literature.

Published
2011

5. Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program

Author

Pollin, Toni I, Isakova, Tamara, Jablonski, Kathleen A, de Bakker, Paul IW, Taylor, Andrew, McAteer, Jarred, Pan, Qing, Horton, Edward S, Delahanty, Linda M, Altshuler, David, Shuldiner, Alan R, Goldberg, Ronald B, Florez, Jose C, Franks, Paul W, Bray, George A, Culbert, Iris W, Champagne, Catherine M, Eberhardt, Barbara, Greenway, Frank, Guillory, Fonda G, Herbert, April A, Jeffirs, Michael L, Kennedy, Betty M, Lovejoy, Jennifer C, Morris, Laura H, Melancon, Lee E, Ryan, Donna, Sanford, Deborah A, Smith, Kenneth G, Smith, Lisa L, St. Amant, Julia A, Tulley, Richard T, Vicknair, Paula C, Williamson, Donald, Zachwieja, Jeffery J, Polonsky, Kenneth S, Tobian, Janet, Ehrmann, David, Matulik, Margaret J, Clark, Bart, Czech, Kirsten, DeSandre, Catherine, Hilbrich, Ruthanne, McNabb, Wylie, Semenske, Ann R, Caro, Jose F, Watson, Pamela G, Goldstein, Barry J, Smith, Kellie A, Mendoza, Jewel, Liberoni, Renee, Pepe, Constance, Spandorfer, John, Donahue, Richard P, Prineas, Ronald, Rowe, Patricia, Calles, Jeanette, Cassanova-Romero, Paul, Florez, Hermes J, Giannella, Anna, Kirby, Lascelles, Larreal, Carmen, McLymont, Valerie, Mendez, Jadell, Ojito, Juliet, Perry, Arlette, Saab, Patrice, Haffner, Steven M, Montez, Maria G, Lorenzo, Carlos, Martinez, Arlene, Hamman, Richard F, Nash, Patricia V, Testaverde, Lisa, Anderson, Denise R, Ballonoff, Larry B, Bouffard, Alexis, Calonge, B Ned, Delve, Lynne, Farago, Martha, Hill, James O, Hoyer, Shelley R, Jortberg, Bonnie T, Lenz, Dione, Miller, Marsha, Price, David W, Regensteiner, Judith G, Seagle, Helen, Smith, Carissa M, Steinke, Sheila C, VanDorsten, Brent, Lawton, Kathleen E, Arky, Ronald A, Bryant, Marybeth, Burke, Jacqueline P, Caballero, Enrique, Callaphan, Karen M, and Ganda, Om P

Subjects
Diabetes, Nutrition, Clinical Research, Prevention, Genetics, Cardiovascular, Metabolic and endocrine, Adult, Cardiovascular Diseases, Cholesterol, HDL, Cholesterol, LDL, Diabetes Mellitus, Type 2, Dyslipidemias, Female, Genetic Association Studies, Humans, Hypoglycemic Agents, Life Style, Lipid Metabolism, Lipoproteins, Magnetic Resonance Spectroscopy, Male, Metformin, Middle Aged, Polymorphism, Single Nucleotide, Risk Factors, Triglycerides, Weight Loss, Diabetes Prevention Program Research Group, Developmental Biology
Abstract

Weight-loss interventions generally improve lipid profiles and reduce cardiovascular disease risk, but effects are variable and may depend on genetic factors. We performed a genetic association analysis of data from 2,993 participants in the Diabetes Prevention Program to test the hypotheses that a genetic risk score (GRS) based on deleterious alleles at 32 lipid-associated single-nucleotide polymorphisms modifies the effects of lifestyle and/or metformin interventions on lipid levels and nuclear magnetic resonance (NMR) lipoprotein subfraction size and number. Twenty-three loci previously associated with fasting LDL-C, HDL-C, or triglycerides replicated (P = 0.04-1 × 10(-17)). Except for total HDL particles (r = -0.03, P = 0.26), all components of the lipid profile correlated with the GRS (partial |r| = 0.07-0.17, P = 5 × 10(-5)-1 10(-19)). The GRS was associated with higher baseline-adjusted 1-year LDL cholesterol levels (β = +0.87, SEE ± 0.22 mg/dl/allele, P = 8 × 10(-5), P(interaction) = 0.02) in the lifestyle intervention group, but not in the placebo (β = +0.20, SEE ± 0.22 mg/dl/allele, P = 0.35) or metformin (β = -0.03, SEE ± 0.22 mg/dl/allele, P = 0.90; P(interaction) = 0.64) groups. Similarly, a higher GRS predicted a greater number of baseline-adjusted small LDL particles at 1 year in the lifestyle intervention arm (β = +0.30, SEE ± 0.012 ln nmol/L/allele, P = 0.01, P(interaction) = 0.01) but not in the placebo (β = -0.002, SEE ± 0.008 ln nmol/L/allele, P = 0.74) or metformin (β = +0.013, SEE ± 0.008 nmol/L/allele, P = 0.12; P(interaction) = 0.24) groups. Our findings suggest that a high genetic burden confers an adverse lipid profile and predicts attenuated response in LDL-C levels and small LDL particle number to dietary and physical activity interventions aimed at weight loss.

Published
2012

6. Targeting BTK through microRNA in chronic lymphocytic leukemia

Author

Bottoni, Arianna, Rizzotto, Lara, Lai, Tzung-Huei, Liu, Chaomei, Smith, Lisa L., Mantel, Rose, Reiff, Sean, El-Gamal, Dalia, Larkin, Karilyn, Johnson, Amy J., Lapalombella, Rosa, Lehman, Amy, Plunkett, William, Byrd, John C., Blachly, James S., Woyach, Jennifer A., and Sampath, Deepa

Published
2016
Full Text
View/download PDF

7. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Author

Woyach, Jennifer A., Smucker, Kelly, Smith, Lisa L., Lozanski, Arletta, Zhong, Yiming, Ruppert, Amy S., Lucas, David, Williams, Katie, Zhao, Weiqiang, Rassenti, Laura, Ghia, Emanuela, Kipps, Thomas J., Mantel, Rose, Jones, Jeffrey, Flynn, Joseph, Maddocks, Kami, O'Brien, Susan, Furman, Richard R., James, Danelle F., Clow, Fong, Lozanski, Gerard, Johnson, Amy J., and Byrd, John C.

Published
2014
Full Text
View/download PDF

8. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Author

Woyach, Jennifer A., Bojnik, Engin, Ruppert, Amy S., Stefanovski, Matthew R., Goettl, Virginia M., Smucker, Kelly A., Smith, Lisa L., Dubovsky, Jason A., Towns, William H., MacMurray, Jessica, Harrington, Bonnie K., Davis, Melanie E., Gobessi, Stefania, Laurenti, Luca, Chang, Betty Y., Buggy, Joseph J., Efremov, Dimitar G., Byrd, John C., and Johnson, Amy J.

Published
2014
Full Text
View/download PDF

9. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Author

Dubovsky, Jason A., Beckwith, Kyle A., Natarajan, Gayathri, Woyach, Jennifer A., Jaglowski, Samantha, Zhong, Yiming, Hessler, Joshua D., Liu, Ta-Ming, Chang, Betty Y., Larkin, Karilyn M., Stefanovski, Matthew R., Chappell, Danielle L., Frissora, Frank W., Smith, Lisa L., Smucker, Kelly A., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami, Lehman, Amy M., Furman, Richard, Sharman, Jeff, Mishra, Anjali, Caligiuri, Michael A., Satoskar, Abhay R., Buggy, Joseph J., Muthusamy, Natarajan, Johnson, Amy J., and Byrd, John C.

Published
2013
Full Text
View/download PDF

10. Genetic heterogeneity of diffuse large B-cell lymphoma

Author

Zhang, Jenny, Grubor, Vladimir, Love, Cassandra L., Banerjee, Anjishnu, Richards, Kristy L., Mieczkowski, Piotr A., Dunphy, Cherie, Choi, William, Au, Wing Yan, Srivastava, Gopesh, Lugar, Patricia L, Rizzieri, David A., Lagoo, Anand S., Bernal-Mizrachi, Leon, Mann, Karen P., Flowers, Christopher, Naresh, Kikkeri, Evens, Andrew, Gordon, Leo I., Czader, Magdalena, Gill, Javed I., Hsi, Eric D., Liu, Qingquan, Fan, Alice, Walsh, Katherine, Jima, Dereje, Smith, Lisa L., Johnson, Amy J., Byrd, John C., Luftig, Micah A., Ni, Ting, Zhu, Jun, Chadburn, Amy, Levy, Shawn, Dunson, David, and Dave, Sandeep S.

Published
2013

12. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway

Author

Lapalombella, Rosa, Andritsos, Leslie, Liu, Qing, May, Sarah E., Browning, Rebekah, Pham, Lan V., Blum, Kristie A., Blum, William, Ramanunni, Asha, Raymond, Chelsey A., Smith, Lisa L., Lehman, Amy, Mo, Xiaokui, Jarjoura, David, Chen, Ching-Shih, Ford, Richard, Jr, Rader, Christoph, Muthusamy, Natarajan, Johnson, Amy J., and Byrd, John C.

Published
2010
Full Text
View/download PDF

13. Patterns of sexual violence against adults and children during the COVID-19 pandemic in Kenya: a prospective cross-sectional study

Author

Rockowitz, Sarah, primary, Stevens, Laura M, additional, Rockey, James C, additional, Smith, Lisa L, additional, Ritchie, Jessica, additional, Colloff, Melissa F, additional, Kanja, Wangu, additional, Cotton, Jessica, additional, Njoroge, Dorothy, additional, Kamau, Catherine, additional, and Flowe, Heather D, additional

Published
2021
Full Text
View/download PDF

14. Evaluating the Reference Interview: A Theoretical Discussion of the Desirability and Achievability of Evaluation.

Author

Smith, Lisa L.

Abstract

Review and examination of the current literature on reference interview evaluation explores the degree to which such evaluative practices are both desirable and achievable. It is concluded that, if both quantitative and qualitative techniques are appropriately used, accurate mechanisms of evaluation are possible and desirable. (17 references) (LRW)

Published
1991

17. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

Author

Lapalombella, Rosa, Yu, Bo, Triantafillou, Georgia, Liu, Qing, Butchar, Jonathan P., Lozanski, Gerard, Ramanunni, Asha, Smith, Lisa L., Blum, William, Andritsos, Leslie, Wang, Da-Sheng, Lehman, Amy, Chen, Ching-Shih, Johnson, Amy J., Marcucci, Guido, Lee, Robert J., Lee, L. James, Tridandapani, Susheela, Muthusamy, Natarajan, and Byrd, John C.

Published
2008
Full Text
View/download PDF

20. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma

Author

Lucas, Fabienne, primary, Rogers, Kerry A., additional, Harrington, Bonnie K., additional, Pan, Alexander, additional, Yu, Lianbo, additional, Breitbach, Justin, additional, Bundschuh, Ralf, additional, Goettl, Virginia M., additional, Hing, Zachary A., additional, Kanga, Parviz, additional, Mantel, Rose, additional, Sampath, Deepa, additional, Smith, Lisa L., additional, Wasmuth, Ronni, additional, White, Danielle K., additional, Yan, Pearlly, additional, Byrd, John C., additional, Lapalombella, Rosa, additional, and Woyach, Jennifer A., additional

Published
2019
Full Text
View/download PDF

22. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Author

Herman, Sarah E.M., primary, Montraveta, Arnau, additional, Niemann, Carsten U., additional, Mora-Jensen, Helena, additional, Gulrajani, Michael, additional, Krantz, Fanny, additional, Mantel, Rose, additional, Smith, Lisa L., additional, McClanahan, Fabienne, additional, Harrington, Bonnie K., additional, Colomer, Dolors, additional, Covey, Todd, additional, Byrd, John C., additional, Izumi, Raquel, additional, Kaptein, Allard, additional, Ulrich, Roger, additional, Johnson, Amy J., additional, Lannutti, Brian J., additional, Wiestner, Adrian, additional, and Woyach, Jennifer A., additional

Published
2017
Full Text
View/download PDF

24. the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Author

Woyach, Jennifer A., primary, Guinn, Daphne, additional, Ruppert, Amy S., additional, Blachly, James S., additional, Lozanski, Arletta, additional, Heerema, Nyla A., additional, Zhao, Weiqiang, additional, Coleman, Joshua, additional, Jones, Daniel, additional, Abruzzo, Lynne V., additional, Gordon, Amber, additional, Mantel, Rose, additional, Smith, Lisa L., additional, McWhorter, Samantha, additional, Davis, Melanie, additional, Doong, Tzyy-Jye, additional, Ny, Fan, additional, Lucas, Margaret S., additional, Chase, Weihong, additional, Jones, Jeffrey, additional, Flynn, Joseph M., additional, Maddocks, Kami J., additional, Jaglowski, Samantha, additional, Andritsos, Leslie A., additional, Awan, Farrukh T., additional, Blum, Kristie, additional, Grever, Michael R., additional, Lozanski, Gerard, additional, Byrd, John C., additional, and Johnson, Amy J., additional

Published
2016
Full Text
View/download PDF

25. Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

Author

McClanahan, Fabienne, primary, Reiff, Sean D., additional, Guinn, Daphne, additional, Tran, Minh, additional, Beaver, Larry, additional, McWorther, Samantha, additional, Mantel, Rose, additional, Smith, Lisa L., additional, Johnson, Amy J., additional, Byrd, John C., additional, and Woyach, Jennifer A., additional

Published
2016
Full Text
View/download PDF

26. The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Author

Reiff, Sean D., primary, Mantel, Rose, additional, Smith, Lisa L., additional, McWhorter, Samantha, additional, Goettl, Virginia M., additional, Johnson, Amy J., additional, Eathiraj, Sudharsan, additional, Abbadessa, Giovanni, additional, Schwartz, Brian, additional, Byrd, John C., additional, and Woyach, Jennifer A., additional

Published
2016
Full Text
View/download PDF

27. The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Author

Rogers, Kerry A., primary, El-Gamal, Dalia, additional, Bonnie, Harrington K., additional, Zachary, Hing A., additional, Virginia, Goettl M., additional, Rose, Mantel, additional, Smith, Lisa L., additional, Yu, Lianbo, additional, Johnson, Amy J., additional, Byrd, John C., additional, Lapalombella, Rosa, additional, and Woyach, Jennifer A., additional

Published
2015
Full Text
View/download PDF

28. Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression.

Author

Dubovsky, Jason A., primary, Beckwith, Kyle A., additional, Natarajan, Gayathri, additional, Woyach, Jennifer A., additional, Jaglowski, Samantha, additional, Hessler, Joshua, additional, Liu, Ta-Ming, additional, Chang, Betty Y., additional, Larkin, Karilyn M., additional, Stefanovski, Matthew R., additional, Frissora, Frank W., additional, Smith, Lisa L., additional, Smucker, Kelly A., additional, Flynn, Joseph M., additional, Jones, Jeffrey A., additional, Andritsos, Leslie A., additional, Maddocks, Kami, additional, Lehman, Amy M., additional, Furman, Richard, additional, Sharman, Jeff, additional, Mishra, Anjali, additional, Caligiuri, Michael A., additional, Satoskar, Abhay R., additional, Buggy, Joseph J., additional, Muthusamy, Natarajan, additional, Johnson, Amy J., additional, and Byrd, John C., additional

Published
2013
Full Text
View/download PDF

29. Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Author

Dubovsky, Jason A, primary, Beckwith, Kyle A, additional, Woyach, Jennifer A., additional, Jaglowski, Samantha M., additional, Hessler, Joshua, additional, Chang, Betty Y., additional, Larkin, Karilyn, additional, Stefanovski, Matthew R, additional, Frissora, Frank W, additional, Smith, Lisa L., additional, Smucker, Kelly A, additional, Flynn, Joseph M., additional, Jones, Jeffrey A., additional, Andritsos, Leslie A, additional, Maddocks, Kami, additional, Lehman, Amy, additional, Furman, Richard R., additional, Sharman, Jeff, additional, Mishra, Anjali, additional, Caligiuri, Michael A., additional, Buggy, Joseph J., additional, Muthusamy, Natarajan, additional, Johnson, Amy J, additional, and Byrd, John C., additional

Published
2012
Full Text
View/download PDF

30. Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Author

Woyach, Jennifer A., primary, Stefanovski, Matthew R, additional, Goettl, Virginia, additional, Ruppert, Amy S., additional, Smucker, Kelly A, additional, Smith, Lisa L., additional, Dubovsky, Jason A, additional, Towns, William H., additional, MacMurray, Jessica, additional, Davis, Melanie E., additional, Mao, Yicheng, additional, Chang, Betty Y., additional, Buggy, Joseph J., additional, Byrd, John C., additional, and Johnson, Amy J, additional

Published
2012
Full Text
View/download PDF

31. Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Author

Johnson, Amy J., primary, Smith, Lisa L., additional, Wagner, Amy J., additional, Hessler, Joshua, additional, Flynn, Joseph M., additional, Jones, Jeffrey A., additional, Zhang, Xiaoli, additional, Lehman, Amy, additional, Jarjoura, David, additional, Grever, Michael R., additional, Bannerji, Rajat, additional, and Byrd, John C., additional

Published
2010
Full Text
View/download PDF

32. The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Author

Flynn, Joseph M., primary, Johnson, Amy J., additional, Andritsos, Leslie, additional, Blum, Kristie A., additional, Jones, Jeffrey A., additional, Wiley, Elizabeth A., additional, Hu, Weihong, additional, Hessler, Joshua, additional, Smith, Lisa L., additional, Lucas, David M., additional, Small, Karen, additional, Statkevich, Paul, additional, Grever, Michael R., additional, Bannerji, Rajat, additional, and Byrd, John C., additional

Published
2009
Full Text
View/download PDF

34. Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Author

Lin, Thomas S., primary, Fischer, Beth, additional, Blum, Kristie A., additional, Andritsos, Leslie A., additional, Jones, Jeffrey A., additional, Moran, Mollie E., additional, Broering, Sarah, additional, Heerema, Nyla A., additional, Lozanski, Gerard, additional, Schaaf, Larry J., additional, Mahoney, Linda S., additional, Johnson, Amy J., additional, Smith, Lisa L., additional, Wagner, Amy J., additional, Raymond, Chelsey A., additional, Phelps, Mitch, additional, Dalton, James T., additional, Grever, Michael R., additional, and Byrd, John C., additional

Published
2007
Full Text
View/download PDF

35. Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Author

Heerema, Nyla A., primary, Byrd, John C., additional, Andritsos, Leslie A., additional, Lozanski, Gerard, additional, Blum, Kristie, additional, Fischer, Beth, additional, Jones, Jeffrey A., additional, Moran, Mollie E., additional, Groering, Sarah, additional, Schaaf, Larry J., additional, Mahoney, Linda S., additional, Johnson, Amy J., additional, Smith, Lisa L., additional, Wagner, Amy J., additional, Raymond, Chelsey A., additional, Phelps, Mitch A., additional, Dalton, James T., additional, Grever, Michael R., additional, and Lin, Thomas S., additional

Published
2007
Full Text
View/download PDF

36. Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.

Author

Lucas, David M., primary, Hussain, Syed-Rehan A., additional, Johnson, Amy J., additional, Smith, Lisa L., additional, Wagner, Amy J., additional, Allison, Jamie M., additional, Guster, Sara E., additional, Lin, Thomas S., additional, Byrd, John C., additional, Julian, Mark W., additional, Crouser, Elliott D., additional, and Grever, Michael R., additional

Published
2006
Full Text
View/download PDF

37. The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL.

Author

Johnson, Amy J., primary, Wagner, Amy J., additional, Smith, Lisa L., additional, Lucas, David M., additional, De Lay, Michael D., additional, Allison, Jamie M., additional, Ivy, S. Percy, additional, Lin, Thomas S., additional, and Byrd, John C., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results